ES2645262T3 - Métodos de uso de CD24 soluble para terapia de artritis reumatoide - Google Patents
Métodos de uso de CD24 soluble para terapia de artritis reumatoide Download PDFInfo
- Publication number
- ES2645262T3 ES2645262T3 ES11778000.7T ES11778000T ES2645262T3 ES 2645262 T3 ES2645262 T3 ES 2645262T3 ES 11778000 T ES11778000 T ES 11778000T ES 2645262 T3 ES2645262 T3 ES 2645262T3
- Authority
- ES
- Spain
- Prior art keywords
- soluble
- methods
- rheumatoid arthritis
- protein
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 title abstract description 6
- 102100038081 Signal transducer CD24 Human genes 0.000 title abstract description 5
- 238000000034 method Methods 0.000 title description 3
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 102000044489 human CD24 Human genes 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 241000713893 Xenotropic murine leukemia virus Species 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000006167 equilibration buffer Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000702619 Porcine parvovirus Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003367 anti-collagen effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000012562 protein A resin Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000011100 viral filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Una proteína CD24 que consiste en una secuencia CD24 humana madura que consiste en SEQ ID NO: 1, fusionada opcionalmente en el extremo C con una región Fc de una proteína inmunoglobulina (Ig) de mamífero, en donde la proteína CD24 no incluye una alanina o una valina inmediatamente C-terminal en la SEQ ID NO: 1.
Description
5
15
25
35
45
55
65
para determinar el rendimiento de CD24-Fc por ELISA.
Captura de proteína A
Se pasó el medio aclarado sobre una columna de resina de Proteína A (GE Healthcare MabSelect) a una concentración no superior a 16 gl/l de resina (basado en ELISA) y un período de contacto de 4 minutos. Se lavó la columna con el tampón de equilibrio (50 mM Tris + 0,15 M NaCl pH 7,5), después con 10 mM citrato sódico /ácido cítrico pH 6,0 durante 5 cvs. Se eluyó CD24Ig unida de la columna utilizando 10 mM citrato sódico /ácido cítrico, pH 3,5.
Inactivación viral
Se llevó inmediatamente la fracción del eluato de Proteína A a un pH 3,0 con la adición de 2M ácido clorhídrico y se mantuvo a este pH durante 30 minutes a temperatura ambiente. Se llevó a un pH 5,0 con la adición de 1M Tris base, y se filtró para el aclarado utilizando un filtro de fibra de vidrio de 0,65 um (Sartorius Sartopure GF2) y 0,2 um (Sartorius Sartopore 2), introduciéndolos en una bolsa colectora estéril.
Cromatografía con SP-Sepharose
Se aplicó el material inactivado viral a una columna de SP-Sepharose (GE Healthcare) a una concentración no superior a 25 g/l de resina (basado en A280 nm de 1,22 = 1 mg/ml) y un caudal lineal de 250 cm/h. Se lavó la columna con el tampón de equilibrio (10 mM citrato sódico / ácido cítrico, pH 5,0) y se eluyó el CD24Ig unido de la columna utilizando 10 mM citrato sódico / ácido cítrico + 0,2 M NaCl, pH 5,0. Se recogió el efluente en una bolsa colectora estéril. .
Cromatografía con Mustang Q
Se ajustó el eluato de SP-Sepharose a pH 7,5 por adición de 1M Tris base y se diluyó con agua para inyectables para reducir la conductividad. Se aplicó el material diluido a una carga de Mustang Q (Pall) a una concentración no superior a 0,5 g/l de resina (basado en A280 nm de 1,22 = 1 mg/ml) y a un caudal de 5 volúmenes de columna / minuto. Se lavó el filtro con un tampón de equilibrio (10 mM Tris, pH 7,5) y se recogió el CD24-Fc contenido en el flujo en una bolsa colectora estéril.
Filtración viral
A continuación, se filtró la resina Mustang Q a una presión constante de 30 psi (207 kPa) a través de un filtro de 0,2 mM y un filtro viral NFP de Millipore (tamaño de poro nominal 20 nm) y se recogió en una bolsa colectora estéril.
Concentración y formulación final
Se concentró el producto y se diafiltró utilizando una membrana de ultrafiltración de 10 kDa (Millipore Prep/Scale) en 10 mM fosfato sódico, 150 mM cloruro sódico, pH 7,2 a aproximadamente 10 mg/ml de concentración final, según se determina por la absorbancia a 280 nm. Se extrajeron muestras para análisis del volumen mientras se encontraba en una cabina de bioseguridad. Se realizó el marcado y se enviaron las muestras a CC para su análisis al mismo tiempo que se almacenaban partes alícuotas en volumen a 2-8 ºC en espera de liberación.
Estudios de aclaramiento viral
Se llevó a cabo el aclaramiento viral en Cardinal Health, Carolina del Norte, en las muesras preparadas en CHM. Investigadores cualificados de Gala Biotech llevaron a cabo las etapas de cromatografía y filtración en las instalaciones de validación viral de Cardinal Health con la ayuda del personal de Cardinal Health. Se desarrolló el procedimiento a menor escala a partir del proceso a una escala de 200 l. Se seleccionaron dos virus para su uso en el estudio. El primero de ellos fue el virus de la leucemia murina xenotrópica (XMuLv), que es un virus de ARN con envoltura de 80-130 nm de tamaño, de la familia viral de los Retroviridae. El segundo fue parvovirus porcino (PPV), que es un virus de ADN sin envoltura de 18-26 nm de tamaño, que se considera un virus robusto y, según lo esperado, debía demostrar una reducción viral mucho menor a través del protocolo de purificación que el virus XMuLv.
Ejemplo 2
Uso de CD24Fc para terapia de AR
Este ejemplo demuestra que se puede utilizar CD24 para tratar AR. Dado que en los pacientes de AR están presentes anticuerpos anti-colágeno antes del inicio de la enfermedad y, dado que los anticuerpos anti-colágeno son capaces de inducir una patología de tipo AR en los ratones, se utilizó el modelo de transferencia pasiva de AR establecido para determinar la eficacia de CD24 soluble. Se disolvió la proteína de fusión en vehículo PBS a 10
7
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32907810P | 2010-04-28 | 2010-04-28 | |
US329078P | 2010-04-28 | ||
PCT/US2011/034282 WO2011139820A1 (en) | 2010-04-28 | 2011-04-28 | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2645262T3 true ES2645262T3 (es) | 2017-12-04 |
Family
ID=44903987
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11778000.7T Active ES2645262T3 (es) | 2010-04-28 | 2011-04-28 | Métodos de uso de CD24 soluble para terapia de artritis reumatoide |
ES17183045T Active ES2826445T3 (es) | 2010-04-28 | 2011-04-28 | Uso médico de CD24 soluble |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES17183045T Active ES2826445T3 (es) | 2010-04-28 | 2011-04-28 | Uso médico de CD24 soluble |
Country Status (18)
Country | Link |
---|---|
US (1) | US8808697B2 (es) |
EP (3) | EP2563385B1 (es) |
JP (5) | JP5899206B2 (es) |
KR (1) | KR20130086126A (es) |
CN (2) | CN102869369B (es) |
AU (1) | AU2011248540B2 (es) |
CA (1) | CA2795823C (es) |
DK (1) | DK2563385T3 (es) |
EA (2) | EA027735B1 (es) |
ES (2) | ES2645262T3 (es) |
HK (2) | HK1176007A1 (es) |
IL (1) | IL222739A0 (es) |
NO (1) | NO2563385T3 (es) |
NZ (1) | NZ603196A (es) |
PL (2) | PL3260128T3 (es) |
PT (2) | PT3260128T (es) |
SG (1) | SG184907A1 (es) |
WO (1) | WO2011139820A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130231464A1 (en) * | 2010-04-28 | 2013-09-05 | Oncolmmune, Inc. | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
ES2829235T3 (es) * | 2015-05-07 | 2021-05-31 | Oncoimmune Inc | Uso de CD24 para disminuir los niveles de colesterol en lipoproteínas de baja densidad |
EP3411062B1 (en) * | 2016-02-02 | 2020-11-25 | Oncoimmune Inc. | Use of cd24 proteins for treating leptin-deficient conditions |
US10758574B2 (en) | 2016-04-28 | 2020-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy |
KR101789449B1 (ko) * | 2016-12-08 | 2017-10-23 | 박문수 | 폐유지를 이용한 지방산 메틸에스테르 제조방법 |
CA3055294A1 (en) * | 2017-03-07 | 2018-09-13 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating systemic lupus erythematosus |
US20200181235A1 (en) * | 2017-05-15 | 2020-06-11 | Oncoimmune, Inc. | Methods of use of soluble cd24 for neuroprotection and remyelination |
CA3064556A1 (en) * | 2017-05-22 | 2018-11-29 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies |
EP3762014A4 (en) * | 2018-03-05 | 2021-08-25 | Oncoimmune, Inc. | METHOD OF USING SOLUBLE CD24 TO TREAT ACQUIRED IMMUNE DEFECTIVITY SYNDROME (HIV / AIDS) |
WO2019236474A1 (en) * | 2018-06-04 | 2019-12-12 | Oncoimmune, Inc. | Methods of use of cd24 for the prevention and treatment of leukemia relapse |
CN112480237B (zh) * | 2019-09-12 | 2023-10-17 | 上海津曼特生物科技有限公司 | 一种融合蛋白及其制备方法和应用 |
WO2023051480A1 (en) * | 2021-09-28 | 2023-04-06 | Acroimmune Guangzhou Biotech Ltd | Fusion proteins comprising 071 core peptide and use thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US5759775A (en) * | 1994-10-27 | 1998-06-02 | Genetech, Inc. | Methods for detecting nucleic acids encoding AL--1 neurotrophic factor |
CN101254302B (zh) * | 1999-05-07 | 2011-05-11 | 杰南技术公司 | 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病 |
US20030106084A1 (en) * | 2000-03-29 | 2003-06-05 | Yang Liu | Methods of blocking tissue destruction by autoreactive T cells |
US20030095966A1 (en) * | 2000-03-29 | 2003-05-22 | Yang Liu | Method of blocking tissue destruction by autoreactive T cells |
DK1267909T3 (da) * | 2000-03-29 | 2010-11-08 | Univ Ohio State Res Found | Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler |
US7189830B2 (en) * | 2001-02-19 | 2007-03-13 | Merck Patent Gmbh | Anti-KSA/IL-2 fusion proteins with reduced immunogenicity |
US20050214290A1 (en) * | 2001-03-29 | 2005-09-29 | Yang Liu | Methods of blocking tissue destruction by autoreactive T cells |
WO2003006047A2 (en) * | 2001-07-13 | 2003-01-23 | Merck Patent Gmbh | Methods for reducing immunogenicity of polypeptides |
AU2003298650B2 (en) * | 2002-11-15 | 2010-03-11 | Musc Foundation For Research Development | Complement receptor 2 targeted complement modulators |
AU2007242919B8 (en) * | 2003-04-09 | 2011-11-10 | F. Hoffmann-La Roche Ag | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor |
US20040202658A1 (en) * | 2003-04-09 | 2004-10-14 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor |
CA2549913A1 (en) | 2003-11-26 | 2005-06-16 | The Ohio State University Research Foundation | Polymorphic cd24 genotypes that are predictive of multiple sclerosis risk and progression |
CA2567496A1 (en) * | 2004-05-21 | 2005-12-01 | Xencor, Inc. | C1q family member proteins with altered immunogenicity |
WO2006053245A2 (en) * | 2004-11-12 | 2006-05-18 | Iogenetics, Llc | Retroviral vectors with introns |
-
2011
- 2011-04-28 CN CN201180021423.6A patent/CN102869369B/zh active Active
- 2011-04-28 ES ES11778000.7T patent/ES2645262T3/es active Active
- 2011-04-28 EA EA201290961A patent/EA027735B1/ru unknown
- 2011-04-28 PL PL17183045T patent/PL3260128T3/pl unknown
- 2011-04-28 PL PL11778000T patent/PL2563385T3/pl unknown
- 2011-04-28 PT PT171830458T patent/PT3260128T/pt unknown
- 2011-04-28 WO PCT/US2011/034282 patent/WO2011139820A1/en active Application Filing
- 2011-04-28 CA CA2795823A patent/CA2795823C/en active Active
- 2011-04-28 DK DK11778000.7T patent/DK2563385T3/da active
- 2011-04-28 PT PT117780007T patent/PT2563385T/pt unknown
- 2011-04-28 AU AU2011248540A patent/AU2011248540B2/en active Active
- 2011-04-28 NZ NZ603196A patent/NZ603196A/en unknown
- 2011-04-28 EP EP11778000.7A patent/EP2563385B1/en active Active
- 2011-04-28 NO NO11778000A patent/NO2563385T3/no unknown
- 2011-04-28 KR KR1020127028301A patent/KR20130086126A/ko not_active Application Discontinuation
- 2011-04-28 SG SG2012077095A patent/SG184907A1/en unknown
- 2011-04-28 EA EA201790538A patent/EA036805B8/ru unknown
- 2011-04-28 ES ES17183045T patent/ES2826445T3/es active Active
- 2011-04-28 US US13/643,527 patent/US8808697B2/en active Active
- 2011-04-28 CN CN201510683408.8A patent/CN105381451B/zh active Active
- 2011-04-28 EP EP17183045.8A patent/EP3260128B1/en active Active
- 2011-04-28 EP EP20188241.2A patent/EP3845238A1/en not_active Withdrawn
- 2011-04-28 JP JP2013508244A patent/JP5899206B2/ja not_active Expired - Fee Related
-
2012
- 2012-10-28 IL IL222739A patent/IL222739A0/en active IP Right Grant
-
2013
- 2013-03-19 HK HK13103375.4A patent/HK1176007A1/zh unknown
- 2013-03-19 HK HK16110735.1A patent/HK1222554A1/zh unknown
-
2015
- 2015-07-09 JP JP2015137457A patent/JP6062502B2/ja not_active Expired - Fee Related
-
2016
- 2016-12-14 JP JP2016242313A patent/JP2017057216A/ja not_active Withdrawn
-
2018
- 2018-05-16 JP JP2018094404A patent/JP6526872B2/ja active Active
-
2019
- 2019-05-08 JP JP2019088170A patent/JP6888221B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2645262T3 (es) | Métodos de uso de CD24 soluble para terapia de artritis reumatoide | |
ES2626268T3 (es) | Método de purificación de proteínas | |
ES2070919T5 (es) | Separacion cromatografica de las proteinas del plasma, principalmente del factor viii, del factor de willebrand de la fibronectina y del fibrinogeno. | |
ES2594408T3 (es) | Método para purificar albúmina sérica humana a partir de grano de arroz transgénico | |
ES2769783T3 (es) | Procedimiento de purificación de inmunoglobulina | |
JP2021074020A (ja) | 安定化された可溶性融合前rsv fポリペプチド | |
AU2011229491B2 (en) | Method for obtaining biologically active recombinant human G-CSF | |
ES2785375T3 (es) | Procedimiento de purificación de inmunoglobulina | |
CN104540846B (zh) | 重新折叠来自包涵体的g‑csf的方法 | |
CN102459331A (zh) | 生产用于皮下使用的高度浓缩的免疫球蛋白制品的方法 | |
ES2924109T3 (es) | Composición que comprende una mezcla de isoformas de CD95-Fc | |
PT1786830E (pt) | Processo para a concentração de anticorpos e produtos terapêuticos dos mesmos | |
CN104530199B (zh) | 一种抗肿瘤多肽及其制备方法和应用 | |
FI60501C (fi) | Foerfarande foer selektiv separering av interferon fraon interferon-raopreparat | |
ES2294696T3 (es) | Metodo de purificacion de albumina que incluye una etapa de nanofiltracion, solucion y composicion para uso terapeutico que la contiene. | |
ES2641042T3 (es) | Procedimiento para la fabricación de un fármaco proteínico | |
ES2569343T3 (es) | Procedimiento para extraer albúmina sérica humana a partir de grano de arroz transgénico | |
CN101497909A (zh) | 制备抗a型肉毒毒素免疫球蛋白抗体的方法 | |
US20130172536A1 (en) | Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof | |
CN103111270B (zh) | 一种乙型肝炎抗原蛋白的吸附材料及其制备方法 | |
ES2717683T3 (es) | Métodos de preparación para una generación novedosa de productos de KLH biológicamente seguros usados para el tratamiento contra el cáncer, para el desarrollo de vacunas terapéuticas conjugadas y como agentes de exposición | |
ES2717709T3 (es) | Métodos de preparación para una generación novedosa de productos de KLH biológicamente seguros usados para el tratamiento de cáncer, para el desarrollo de vacunas terapéuticas conjugadas y como agentes de exposición | |
CN112375142A (zh) | 静注新型冠状病毒人免疫球蛋白的制备方法 | |
JPH08505389A (ja) | ヒトrsウイルスのfg糖蛋白質の精製および再生方法 | |
RU2005115752A (ru) | Способ получения препарата иммуноглобулина для внутривенного введения и препарат, получаемый этим способом |